US Stock MarketDetailed Quotes
PSTV Plus Therapeutics
- 1.3500
- +0.0350+2.66%
Close Nov 1 16:00 ET
- 1.3500
- 0.00000.00%
Post 20:02 ET
7.96MMarket Cap-436P/E (TTM)
1.3700High1.3200Low15.27KVolume1.3300Open1.3150Pre Close20.74KTurnover0.27%Turnover RatioLossP/E (Static)5.90MShares2.780052wk High-1.04P/B7.76MFloat Cap1.145052wk Low--Dividend TTM5.75MShs Float7507.4985Historical High--Div YieldTTM3.80%Amplitude0.9690Historical Low1.3580Avg Price1Lot Size
Plus Therapeutics Stock Forum
Sign in to post a comment
$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy
Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy
ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New Y...
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
Rhenium (186Re) Obisbemeda delivered by convection enhanced delivery (CED) continues to show safety, response, and potential efficacy
Mean Phase 2 absorbed dose was 300 Gy and 89% of patients exceeded the minimal dose threshold of 100 Gy
ReSPECT-GBM Phase 1/2 trial has expanded to two new sites at leading U.S. academic medical centers in New Y...
1
1
Plus Therapeutics Announces Encouraging Clinical Trial Outcomes at the 2024 SNO/ASCO CNS Metastases Conference.
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently presented promising data from their ReSPECT-LM clinical trial at the 2024 Society for Neuro-Oncology (SNO) and American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The trial focuses on evaluating the sa...
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, recently presented promising data from their ReSPECT-LM clinical trial at the 2024 Society for Neuro-Oncology (SNO) and American Society for Clinical Oncology (ASCO) CNS Metastases Conference. The trial focuses on evaluating the sa...
$Plus Therapeutics (PSTV.US)$
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide in...
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
Plus Therapeutics (NASDAQ: PSTV) presented positive results from the FORESEE study of its CNSide platform for diagnosing and managing leptomeningeal metastases (LM) at the 2024 SNO/ASCO CNS Metastases Conference. The trial, involving 39 patients with breast or non-small cell lung cancer, met its primary and secondary endpoints. Key findings include:
CNSide in...
1
$Plus Therapeutics (PSTV.US)$ Benzinga· 1 min ago
Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference
Plus Therapeutics Presented Data In Podium Presentation Updating The Progress Of Its ReSPECT-LM Trial Of Rhenium Obisbemeda In Leptomeningeal Disease At The 2024 Society For NeuroOncology/American Society For Clinical Oncology CNS Metastases Conference
1
1
$Plus Therapeutics (PSTV.US)$ Plus Therapeutics (PSTV) said Friday it received notice of a $3.3 million advance payment from the Cancer Prevention & Research Institute of Texas, or CPRIT, as part of a $17.6 million grant awarded in September 2022.
The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.
The company said the funding will support the leptomeningeal cancer radiotherapeutic development program and CNSide testing in the ReSPECT-LM trial.
1
$Plus Therapeutics (PSTV.US)$ Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1.09) by 31.19 percent. This is a 63.77 percent increase over losses of $(2.07) per share from the same period last year. The company reported quarterly sales of $1.677 million which missed the analyst consensus estimate of $1.688 million by 0.62 percent. This is a 231.42 percent increase over sales of $506.000 thousand the same period last ye...
1
2
$Plus Therapeutics (PSTV.US)$
NEWS
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Positive Acquisition of CNSide™ diagnostic platform to enhance LM diagnostic accuracy. Successful presentation of topline data from the FORESEE trial meeting primary endpoint. Potential partnering opportunities for CNSide™ to expand market size. Expected attractive near-term return on investment for stockholders. Negative Cur...
NEWS
Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial
Positive Acquisition of CNSide™ diagnostic platform to enhance LM diagnostic accuracy. Successful presentation of topline data from the FORESEE trial meeting primary endpoint. Potential partnering opportunities for CNSide™ to expand market size. Expected attractive near-term return on investment for stockholders. Negative Cur...
$Plus Therapeutics (PSTV.US)$
NEWS
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Positive
Strategic acquisition of C...
NEWS
Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
Plus Therapeutics, Inc. (Nasdaq: PSTV) will host an investor call on May 9th, 2024, to discuss the acquisition of CNSide assets and provide updates on the FORESEE clinical trial. The company aims to leverage the acquired assets for CNS cancers and share key insights with investors.
Positive
Strategic acquisition of C...
Plus Therapeutics Secures Up to $18 Million Through Strategic Private Financing.
To bolster its financial position and further its research in targeted radiotherapeutics, Plus Therapeutics, Inc. (Nasdaq: PSTV), based out of Austin, Texas, has announced a substantial private placement financing agreement. The deal, set to raise up to approximately $18 million in gross proceeds, has been orchestrated with the support of ne...
To bolster its financial position and further its research in targeted radiotherapeutics, Plus Therapeutics, Inc. (Nasdaq: PSTV), based out of Austin, Texas, has announced a substantial private placement financing agreement. The deal, set to raise up to approximately $18 million in gross proceeds, has been orchestrated with the support of ne...
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
151479178 : Do you know why *the price has recently/ is fluctuating so much?